Status:

COMPLETED

SPECT Study With SB-773812 In Schizophrenic Patients

Lead Sponsor:

GlaxoSmithKline

Conditions:

Schizophrenia

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This study is being conducted in 2 groups of schizophrenic patients: in group 1 the relationship between the dopaminergic D2 receptor occupancy (D2 RO ) and serotoninergic 5HT2A receptor occupancy at ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • schizophrenic patients as diagnosed by DSM IV criteria.
  • In group 2, subject has schizophrenia or schizophreniform disorder and show moderate disease exacerbation, a PANSS score \> 65 and a score in the PANSS positive scale (PANSS-P) =25.
  • Women of childbearing potential must agree to acceptable method of birth control.
  • Exclusion criteria:
  • Subject shows severe exacerbation, extreme instability, high risk for suicide or serious violent behaviour.
  • Any clinically or laboratory significant abnormality.
  • Subjects receiving a radiation dose from other activities of more than 10 mSv over any 3 year period.
  • Subjects with organic brain disease and history of severe head trauma.
  • Heart pacemaker, metallic prosthesis or other metallic body implants.
  • Significant head deformity.
  • Smokers with associated COPD.
  • History or presence of clinically significant gastro-intestinal, hepatic or renal disease.
  • History of cholecystectomy or biliary tract disease.
  • Positive for HBV, HCV or HIV.
  • Pregnant or lactating women.

Exclusion

    Key Trial Info

    Start Date :

    June 21 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 26 2007

    Estimated Enrollment :

    95 Patients enrolled

    Trial Details

    Trial ID

    NCT00269035

    Start Date

    June 21 2005

    End Date

    May 26 2007

    Last Update

    August 17 2017

    Active Locations (6)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (6 locations)

    1

    GSK Investigational Site

    Barcelona, Spain, 08003

    2

    GSK Investigational Site

    Barcelona, Spain, 08025

    3

    GSK Investigational Site

    Barcelona, Spain, 08035

    4

    GSK Investigational Site

    Mataro (Barcelona), Spain